653563-78-1

Upstream product

• 587832-07-3 (+)-methyl-2-[4-phenylmethoxy-phenoxy]-2-methyl butyrate 
• 67-56-1 methanol 
• 908150-18-5 (R)-2-[4-phenylmethoxyphenoxy]-2-methyl butyric acid R-(-)-phenylglycinol salt 
• 653563-75-8 methyl (4-(benzyloxy)phenoxy)-2-methylbutanoate 
• 653563-74-7 methyl 2-(4-(benzyloxy)phenoxy)butanoate 
• 653563-76-9 methyl 2-(4-hydroxyphenoxy)-2-methylbutanoate 
• 103-16-2 4-Benzyloxyphenol 
• 3196-15-4 Methyl 2-bromobutyrate 

Relevant academic research and scientific papers

Process for the preparation of optically pure isomers of 2-(4-hydroxy phenoxy)-2-methyl-butyric acid methyl ester

The invention provides a process for preparing R-(+)-2-(4-hydroxyphenoxy)-2-methyl-butyric acid methyl ester of the formula (1): Various embodiments and variants are provided. The invention also provides a process for preparing S-(?)-2-(4-hydroxyphenoxy)-

NOVEL ISOXAZOLE COMPOUNDS HAVING PPAR AGONIST ACTIVITY

The present invention relates to novel isoxazole compounds of formula (I) having (PPAR) agonist activity, pharmaceutical compositions containing such compounds and methods for their use.

Design and synthesis of potent and subtype-selective PPARα agonists

Beginning with a moderately potent PPARγ agonist 9, a series of potent and highly subtype-selective PPARα agonists was identified through a systematic SAR study. Based on the results of the efficacy studies in the hamster and dog models of dyslipidemia and the desired pharmacokinetic data, the optimized compound 39 was selected for further profiling.

PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS

A class of chromane and chromene compounds having the structure shown below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia,